Mobile

A study of talimogene laherparepvec in pediatric subjects with tumors that are able to be directly injected and do not occur in the spinal cord or brain

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003645-25

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the safety and tolerability of talimogene laherparepvec, as assessed by incidence of dose-limiting toxicities (DLT), in pediatric subjects with advanced non central nervous system (CNS) tumors that are amenable to direct injection.

Critère d'inclusion

  • Non-Central Nervous System (CNS) Tumors

Liens